Paid Clinical Trials South Dakota
Discover 345 paid clinical trials in South Dakota. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLCTo Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Sponsor:
Shanghai Henlius Biotech
Location:
Code:
NCT05468489
Conditions
Extensive Stage Small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Serplulimab + chemotherapy (carboplatin-etoposide)
Atezolizumab + chemotherapy (carboplatin-etoposide)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT06065748
Conditions
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Giredestrant
Fulvestrant
Abemaciclib
Palbociclib
Ribociclib
Measuring Outcomes of LASIK and EVO-ICL in Matched PopulationsMeasuring Outcomes of LASIK and EVO-ICL in Matched Populations
Sponsor:
Vance Thompson Vision
Location:
Code:
NCT06700460
Conditions
Myopia
Eligibility Criteria
Sex: All
Age: 21 - 45
Healthy Volunteers: Not accepted
Interventions
Laser-assisted in Situ Keratomileusis
Implantable Collamer Lens placement
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic CancerA Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Sponsor:
Takeda
Location:
Code:
NCT04844073
Conditions
Squamous Cell Cancer of Head and Neck (SCCHN)
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TAK-186
PTSD, AUD, and Interpersonal Conflict: Within-person AssociationsPTSD, AUD, and Interpersonal Conflict: Within-person Associations
Sponsor:
University of South Dakota
Location:
Code:
NCT04552782
Conditions
Stress Disorders, Post-Traumatic
Alcoholism
Eligibility Criteria
Sex: All
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Alcohol CBM
PTSD CBM
Alcohol Sham
PTSD Sham
Safety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet JointSafety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet Joint
Sponsor:
InGeneron, Inc.
Location:
Code:
NCT03513731
Conditions
Osteoarthritis of Facet Joint of Lumbar Spine
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Adipose-derived stem cell injection
Corticosteroid injection
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Sponsor:
Karyopharm Therapeutics Inc
Location:
Code:
NCT05611931
Conditions
Endometrial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Selinexor
Matching Placebo for selinexor
Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
Sponsor:
Vertex Pharmaceuticals Incorporated
Location:
Code:
NCT06506773
Conditions
Cystic Fibrosis
Eligibility Criteria
Sex: All
Age: 0 - 6
Healthy Volunteers: Not accepted
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesA Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Sponsor:
Novo Nordisk A/S
Location:
Code:
NCT06542874
Conditions
Type 2 Diabetes (T2D)
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
NNC0487-0111 subcutanous
Placebo (NNC0487-0111 subcutanous)
NNC0487-0111 oral
Placebo (NNC0487-0111 oral)